HRT Financial’s Co-Diagnostics CODX Stock Holding History

HRT Financial’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,170	Closed	-$313K	–	3209
2021 Q4	$313K	Buy	+1,170	New	+$307K	﹤0.01%	2241

Other funds holding CODX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAG

Private Advisory Group Redmond, Washington $1.52B AUM 41.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HRT Financial's CODX Position: Q4 2025 in Review

HRT Financial sold out of Co-Diagnostics (CODX) in Q4 2025, closing a stake of 4,976 shares — an estimated $51K sold.

HRT Financial first reported a position in CODX in Q2 2021 and held it in 8 quarters. The position peaked at $637K in Q2 2021. 30 funds tracked by Wall St. Rank hold CODX as of Q4 2025.

HRT Financial reported no remaining Co-Diagnostics position as of Q4 2025 after selling out during the quarter.
HRT Financial sold 4,976 Co-Diagnostics shares in Q4 2025, an estimated $51K.
HRT Financial first reported a position in Co-Diagnostics in Q2 2021 and held it in 8 quarters.
HRT Financial's Co-Diagnostics position peaked at $637K in Q2 2021.
30 funds tracked by Wall St. Rank held Co-Diagnostics as of Q4 2025.

Based on HRT Financial's 13F filing for Q4 2025, filed 12 Feb 2026.